The ‘Ripple Effect’ of the COVID-19 pandemic on clinical trials

Clinical trials are the engine room that powers our ability to deliver new treatment options to patients. The rigorous testing and resulting data that help us understand how new treatments work are what propels our industry forward.

Patient advocates: hard hit at the time of greatest need

With reduced capacity and opportunity for fundraising, extra pressure on support services and attention diverted elsewhere, it will take a long time for them to recover and return to business as usual.

Adjusting launch planning in light of clinical trial delays

Clinical trial delays not only impact the current path forward but potentially (depending on the extent of the delay/disruption) can create hurdles for future regulatory filing, approval and launch. Therefore, as with all functions being affected by the pandemic, adaptability will be critical.

Best practices for communicating clinical trial changes and delays

In the case of COVID-19, clinical trials – like many other planned activities – have been impacted and many companies have been forced to make some tough choices. When making the difficult, yet necessary, decision to delay a trial, communicating clearly and strategically across all affected audiences is critically important.

Telehealth comes to the forefront

Telehealth, in particular, has been waiting for its moment. In the U.S., the first recorded instance of telemedicine happened more than 60 years ago (!) when the Nebraska Psychiatry Institute began using closed-circuit TV for psychiatric consultations.